Peer-review articles

 

  • Janas C, Mast MP, Kirsamer L, Angioni C, Gao F, Mäntele W, Dressman J, Wacker MG (2017); The dispersion releaser technology is an effective method for testing the drug release from nanosized carriers, Eur. J. Pharm. Biopharm. 115:73-83.
  • Beyer S, Xie L, Schmidt M, de Bruin N, Ashtikar M, Rüschenbaum S, Lange CM, Vogel V, Mäntele W, Parnham MJ, Wacker MG; Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques, J. Control. Release, 10 (235):352-364.

  • Wacker MG, Proykova A, Santos GM (2016); Dealing with nanosafety around the globe – Regulation vs. Innovation, Int. J. Pharm. 509(1-2):95-106.
  • Janas C, Mostaphaoui Z, Schmiederer L, Bauer J, Wacker MG (2016); Novel polymeric micelles for drug delivery: Material characterization and formulation screening, Int. J. Pharm. 509(1-2)197-207.
  • Beyer S, Moosmann A, Kahnt AS, Ulshöfer T, Parnham MJ, Ferreirós N, Wacker MG (2015); Drug release and targeting: The versatility of polymethacrylate nanoparticles for peroral administration revealed by using an optimized in vitro-toolbox, Pharm. Res. 32(12):3986-3998.
  • Bergs JW, Wacker MG, Hehlgans S, Piiper A, Multhoff G, Rödel C,Rödel F (2015); The role of recent nanotechnology in enhancing the efficacy of radiation therapy, Biochim. Biophys. Acta 1856(1):130-143.
  • Villa Nova M, Janas C, Schmidt M, Ulshöfer T, Gräfe S, Schiffmann S, de Bruin N, Wiehe A, Albrecht V, Parnham MJ, Bruschi ML, Wacker MG (2015); Nanocarriers for photodynamic therapy - Rational formulation design and medium-scale manufacture, Int. J. Pharm. 491(1-2):250-260.
  • Xie L, Beyer S, Vogel V, Wacker MG, Mäntele W (2015); Assessing the Drug Release from Nanoparticles: Overcoming the Shortcomings of Dialysis by Using Novel Optical Techniques and a Mathematical Model, Int. J. Pharm. 488(1-2): 108-19
  • Beyer S, Xie L, Graefe S, Vogel V, Dietrich K, Wiehe A, Albrecht V, Maentele W, Wacker MG (2015); Bridging Laboratory and Large Scale Production: Preparation and In Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery, Pharm. Res. 32(5):1714-1726
  • Wacker MG, Altinok M, Urfels S, Bauer J (2014); Nanoencapsulation of superparamagnetic particles of iron oxide into human serum albumin nanoparticles, Beilstein J. Nanotechnol. 5:2259-66
  • Wacker MG; Hund-Rinke K, Creutzenberg O (2014); Quo vadis Nano? Nanomaterialien in der pharmazeutische Produktentwicklung, Pharm. Ind.7: 1134-1140
  • Wacker MG; Nanotherapeutics - Product development alo.ng the ‘nanomaterial’ discussion (2014), J. Pharm. Sci. 103(3):777-784
  • Wacker M (2013); Nanocarriers for intravenous injection – The long hard road to the market, Int. J. Pharm. 457(1):50-62.
  • Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C,Gehrmann M, Rödel C, Kreuter J, Rödel F (2013); Targeting by cmHsp70.1-antibody coated and Survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells, J. Control. Release 172(1):201-206.
  • Hofmann B, Rödl CB, Fischer AS, Maier TJ, Michel AA, Hoffmann M, Rau O, Awwad K, Pellowska M, Wurglics M, Wacker M, Živković A, Fleming I, Schubert-Zsilavecz M, Stark H, Schneider G, Steinhilber D (2012); Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor, Br. J. Pharmacol. 165(7):2304-2313.
  • Wacker M, Zensi A, Kufleitner J, Ruff A, Schütz J, Stockburger T, Marstaller T, Vogel V (2011); A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation, Int. J. Pharm. 414(1-2):225-232.
  • Löw K, Wacker M, Wagner S, Langer K, von Briesen H (2011); Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells, Nanomedicine 7(4):454-463.
  • Preuss A, Hackbarth S, Wacker M, Knobloch T, Langer K, Röder B (2010); Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems, J. Control. Release 148(1):117-118.
  • Zheng SZ, Löw K, Wacker M, Wiehe A, Wagner S, Langer K, von Briesen H, Zou SQ (2010); Interaction and cytotoxicity of mTHPC and mTHPC complexes in Jurkat cells. Chin. J. Exp. Surg. 27:13-22.
  • Chen K, Wacker M, Hackbarth S, Ludwig C, Langer K, Roeder B (2010); Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems, J. Photochem. Photobiol. B 101(3):340-347.
  • Wacker M, Chen K, Preuss A, Possemeyer K, Roeder B, Langer K (2010); Photosensitizer loaded HSA nanoparticles I: Preparation and photophysical properties, Int. J. Pharm. 93(1-2):253-262.
  • Chen K, Preuss A, Hackbarth S, Wacker M, Langer K, Roeder B (2009); Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations, J. Photochem. Photobiol. B 96(1):66-74.

 

Patents and patent applications

  • Wacker MG, Beyer S, Xie L, Vogel V, Maentele W, Parnham MJ; Composition comprising biocompatible and biodegradable polymer, nanocarriers and a drug and methods of making and using the same, European Patent Application (FH13533EP)
  • Wacker MG, Janas C; Adapter für die Freisetzung disperser Arzneizubereitungen (Dispersion Releaser), German Patent 2015 (DE102013015522 A1) / PCT application 2014 (PCT/EP2014/002523)
  • Langer K, Wacker M, Röder B, Preuss A, Albrecht V, Gräfe S, Wiehe A, von Briesen H, Löw K, Wagner S; Nanoparticle carrier systems based on human serum albumin for photodynamic therapy (US 2011/0142948 A1)

 

Abstracts and presentations

 

  • Wacker MG (2017); Safety & Regulatory Aspects of Nanomedicines, NUS workshop Nanomedicines - Understanding the technical & regulatory perspectives for better translation, Singapore

  • Wacker MG (2017); Challenges in the drug release testing of next-generation nanomedicines, FIP/USP/AAPS workshop Nanomedicines - Technical and Regulatory Perspectives, Rockville, USA

  • Wacker MG (2016); Designing nanocarriers for drug delivery, NRW-Nanokonferenz, Münster, Germany

  • Wacker MG (2016); Challenges in the drug release testing of next generation nanomedicines, DECHEMA platform NanoBioMedizin, Frankfurt, Germany

  • Nothnagel L, Thurn M, Wacker MG (2016); DoE-based development and in vitro drug release testing of TMP-001 loaded nanocarriers, GPEN Annual Meeting 2016, Lawrence, Kansas, USA

  • Jablonka L, Thurn M, Wacker MG (2016); In vitro drug release testing of liposomal temoporfin formulations with the dispersion releaser technology, GPEN Annual Meeting 2016, Lawrence, Kansas, USA

  • Wacker MG (2016), ANVISA discussion group on "Nanomedicines", Brasilia, Brazil

  • Wacker MG (2016), Designing Nanomedicines for the Market, Drug Delivery & Formulation Summit, Berlin, Germany

  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, Pharma Test Indonesia Workshop, Jakarta, Indonesia

  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, Matrix Analytical Technologies Workshop, Kuala Lumpur, Malaysia

  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, 1st LOSAN Drug Delivery Conference on Formulation Technologies, Frankfurt, Germany

  • Wacker MG (2015), Die neue Nanomedizin - Von der Idee zum Produkt, Treffen der Deutschen Plattform NanoBioMedizin, Frankfurt, Germany

  • Wacker MG (2015), Nanocarrier for Drug Delivery - Rational Formulation Design, University of Namibia, Windhoek, Namibia (Invited presentation)

  • Wacker MG (2015), Nanocarriers for Drug Delivery - Rational Formulation Design, 1st International Symposium on Drug Delivery Systems (SISLiF), Maringá, Brazil

  • Wacker MG (2015), Pharmazeutische Technologie "Quo Vadis Nano?", IHK-Event / Zu Gast beim LOEWE-Zentrum Translationale Medizin und Pharmakologie, Frankfurt, Germany

  • Wacker MG (2015), Parenteralia, Ophthalmika und perorale Suspensionen - Stabilität, Teilchengrößenwachstum und Freisetzung, FAH Workshop - Pharmaproduktion und Partikel, Bonn, Germany

  • Wacker MG (2015), Nanocarriers for Cancer Therapy - Rational Formulation Design, Evonik-LOSAN Workshop, Darmstadt, Germany

  • Wacker MG (2015), Nanocarriers for Drug Delivery - Rational Formulation Design, Drug Delivery and Formulation Global Summit, Düsseldorf, Germany

  • Wacker MG (2014), Rational Formulation Design - Nanomedizin mal anders!, DPhG Seminar, Freiburg, Germany

  • Beyer S, Wacker MG (2014), Nanocarriers for Drug Delivery - Rational Formulation Design, International Conference on Advances and Progress in Human Health Management and Healthcare Reforms (ADICON), Sagar, India

  • Janas C, Dressman JB, Wacker MG (2014), The Dispersion Releaser: An Optimal Tool for Selection of Colloidal Dosage Forms, Globalization of Pharmaceutics Education Network (GPEN) Nineth Meeting, Helsinki, Finland

  • Beyer S, Gräfe S, Albrecht V, Wacker MG (2014), Accepting the Challenge of Scale-up - A New Approach for the Targeted Treatment of Colon Cancer based on Nanoparticles overcomes the Limitations of Batch Size, Controlled Release Socienty Annual Meeting, Chicago, USA

  • Wacker MG (2014), Rational Formulation Design - Nanomedizin mal anders!, Neue Potentiale für die Nanotechnologie in der Medizin, Darmstadt, Germany

  • Wacker MG, Parnham MJ (2014), Achieving a Good Working Relationship with an Academic Research Organization, Drug Delivery & Formulation Americas Summit, San Diego, USA

  • Janas C, Dressman JB, Wacker M (2013); Innovative Nanocarrier Systems for the Delivery of Temoporfin: In vitro selection and formulation refinement, American Association of Pharmaceutical Scientists (AAPS) Annual meeting and exposition, San Antonio, USA

  • Wacker M (2013); Nanocarrier - Entwicklung und Optimierung innovativer Arzneistoffträger, PharmaForum Hessen 2013, Mainz, Germany

  • Beyer S, Ferreirós Bouzas N, Kahnt AS, Wacker M (2013); Polymethacrylic acid-based nanoparticles for the peroral delivery of flurbiprofen – physicochemical properties and evaluation in cell culture models, 40th Annual Meeting and Exposition of the Controlled Release Society 2013, Honolulu, USA

  • Beyer S, Vogel V, Schlupp P, Engelmann V, Baumstümmler B, Türeli A, Wieland G, Wiehe A, Gräfe S, Albrecht V, Runkel F, Wacker M  (2013); Eudragit nanoparticles for photodynamic therapy: optimization of formulation design and manufacture, 40th Annual Meeting and Exposition of the Controlled Release Society 2013, Honolulu, USA

  • Wacker M (2013) Nanocarrier - Trends in Modern Formulation Development, Innovative Dosage Forms in Development and Production Workshop, Essen, Germany

  • Janas C, Wacker M (2012), Rational Design of Nanoparticle Dissolution Testing: The challenge of in vitro drug release, DPhG Doktorandentagung, Greifswald, Germany

  • Beyer S, Wacker M (2012), Eudragit nanoparticles - An advanced controlled release carrier system for non-steroidal anti-inflammatory drugs (NSAIDs), Pharma Forum Hessen 2012, Hanau, Germany

  • Beyer S, Dietrich K, Wacker M (2012), Manufacture of porphyrin-loaded Eudragit nanoparticles - A mucoadhesive drug delivery system. Controlled Release Society (CRS) German Chapter Annual Meeting, Würzburg, Germany

  • Dietrich K, Wacker M (2012), Manufacture of porphyrin-loaded Eudragit nanoparticles - A mucoadhesive drug delivery system. 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology 2012, Istanbul, Turkey

  • Wacker M (2011); Nanopartikel - Eine neue Alternative in der peroralen Arzneistoffformulierung, Pharmaforum 2011 Saarland, St. Ingbert, Germany

  • Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation. 38th Annual Meeting and Exposition of the Controlled Release Society 2011, National Harbor, USA

  • Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation. DPhG Doktorandentagung 2011, Heringsdorf, Germany

  • Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation. Controlled Release Society (CRS) German Chapter Annual Meeting, Jena, Germany

 

Other publications and authorships

Contact information

 

Dr. Matthias G. Wacker

Goethe University
Institute of Pharmaceutical Technology

Max-von-Laue-Str. 9
D-60438 Frankfurt

 

Phone: +49 (0) 69 - 798 - 29691
Fax       +49 (0) 69 - 798 - 29694

Email: info [a] nanomedicines.de

Druckversion Druckversion | Sitemap
Nanosized drug delivery